Genomic Analysis of AZD1222 (ChAdOx1) Vaccine Breakthrough Infections in the City of Mumbai
Table 2
Distribution of severe COVID-19 according to clinical and genomic variables (n = 159, continuous variables were dichotomized based on the median value).
Category
Univariable analysis
Multivariable analysis
% severe disease, odds ratio (95% CI)
value
Odds ratio (95% CI)
value
Age (≥36 (n = 80) vs. < 36 (n = 79) years)
15.0% vs. 2.5%, 6.79 (1.47–31.44)
0.009
5.71 (1.41–38.57)
0.03
Gender (male (n = 81) vs. female (n = 78))
11.1% vs. 6.4%, 1.83 (0.58–5.71)
0.40
1.50 (0.46–5.40)
0.51
Ct value of the E gene (<22.5 (n = 79) vs. ≥ 22.5 (n = 80))
7.5% vs. 10.0%, 0.74 (0.24–2.24)
0.78
Ct value of the N gene (<23 (n = 80) vs. ≥ 23 (n = 79))
8.7% vs. 8.8%, 0.99 (0.33–2.95)
0.99
Total no. of amino acid mutations per sample (≥22 (n = 83) vs. < 22 (n = 76))
8.4% vs. 9.2%, 0.91 (0.30–2.72)
0.99
Diabetes (presence (n = 14) vs. absence (n = 145))
14.2% vs. 8.2%, 1.85 (0.37–9.23)
0.36
Hypertension (presence (n = 15) vs. absence (n = 144))
6.6% vs. 9.0%, 0.72 (0.09–5.92)
0.99
Malignancy (presence (n = 29) vs. absence (n = 130))
20.6% vs. 6.1%, 3.98 (1.26–12.54)
0.02
1.98 (0.53–7.25)
0.30
Comorbidity (presence of any comorbidity (n = 58) vs. absence of all comorbidities (n = 101))
12.0% vs. 6.9%, 1.84 (0.61–5.54)
0.38
Vaccination status (vaccinated (n = 67) vs. unvaccinated (n = 92))
